Dojindo Molecular Technologies, Inc.

Marin Biologic blends the fields of cell biology, immunology, molecular biology and biochemistry to tackle complex projects in an innovative and timely manner. We simultaneously utilize our in-depth scientific expertise to collectively approach projects to complement our client’s approach and meet the client’s needs.

Marin Biologic is a woman PhD owned and managed Contract Research Laboratory which specializes in the research, pre-clinical and clinical development and validation of cell based assays and immunoassays for biotech and pharmaceutical companies in Phase I/II or Phase III stages. Our unique approach to collaboration encourages scientists to talk to scientists to create better science.

We are compliant with U.S. FDA cGMP/GLP standards as well as ICH for all levels of clinical development. We employ these standards that are phase appropriate for your clinical development or research.

CEO and President Tania Weiss PhD founded Marin Biologic Laboratories in 1995 to be able to apply her enthusiasm for good scientific process to a broad array of client projects. As a result, the client list as well as the project list is very diverse over the history of the Company. Marin Biologic seeks out and attracts interesting and different scientific opportunities, which puts them at the forefront of scientific development.

Our Lab is located in Novato, California, halfway between San Francisco and the Napa and Sonoma Valleys.

Peter Ralph. PhD, VP Science, peter@marinbio.com
Tania Weiss, PhD, CEO, tania@marinbio.com

415 883-8000
Visit: www.marinbio.com to connect with us, or ask us a question.

AcceGen Biotech proudly develops innovative technologies for the pharmaceutical, biotech and specialty ingredients markets. We are committed to supplying the best products and services with global manufacturing, development expertise and advanced technologies to enhance the overall quality of life.

AcceGen Biotech developed significant expertise in cell and genomic research. We provide a variety of high-quality human/animal cells, cell media/kits, cell-derived molecular biology products, gene-based assay kits, Clones, Fish probes and Sequencing products for research use.

AcceGen Biotech offers custom cell line generation, microRNA sponges and microRNA Agomir/Antagomir services to simplify the gene research. The aim is to accelerate scientific discovery related to genetic analysis available to academic researchers as well as commercial enterprises.

AcceGen Biotech has permanent facilities in Fairfield (New Jersey). We take care of our customers and their global, regional or local requirements. We welcome potential partners and distributors to explore our business all over the world.

ACD - a Bio-Techne brand, (www.acdbio.com) shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA.

ACD is a leader in the emerging field of molecular pathology, developing cell- and tissue-based research and diagnostic tests for personalized medicine. Based in Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.

ACD’s products and pharma assay services are based on its proprietary RNAscope® technology ( 1200+ publications in 6 years), the first multiplex fluorescent and chromogenic in situ hybridization platform, capable of detecting and quantifying single molecules of RNA in situ. ACD has two product lines, namely RNAscope and BaseScope(tm) in addition to a Pharma Assay Services business. The catalog includes >10,000 target probes and assay kits for single, duplex and multiplex RNA analysis.

www.acdbio.com

Affina Biotechnologies is dedicated to excellence in helping our customers develop measurements of activities, kinetics and affinities of interactions and concentrations of biomolecules. We offer a unique mix of label-free and label-dependent assay technologies supported by scientific and technical expertise and a wide range of instrumentation:

Surface Plasmon Resonance (SPR)
Light absorbance, luminescence, fluorescence polarization, time-resolved fluorescence
Affina scientists will work with you on developing custom-built measurements and screens that are tailored to your requirements. Once a method is developed and validated we will help you transfer it to your facility of choice or perform it at Affina. The services listed are the major ones that we provide. If there is a type of measurement that can use our technologies and is not listed here we will be happy to work on it with you!

Affinity and kinetics of molecular interactions
Enzyme activity
Total and active concentration

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.

MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.

Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free.

Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.

For view our social media policies, please visit https://agendia.com/legal-compliance/